[go: up one dir, main page]

WO2008132458A8 - Compositions useful in the modulation of immune responses and the treatment or prevention of inflammatory responses and related methods - Google Patents

Compositions useful in the modulation of immune responses and the treatment or prevention of inflammatory responses and related methods Download PDF

Info

Publication number
WO2008132458A8
WO2008132458A8 PCT/GB2008/001460 GB2008001460W WO2008132458A8 WO 2008132458 A8 WO2008132458 A8 WO 2008132458A8 GB 2008001460 W GB2008001460 W GB 2008001460W WO 2008132458 A8 WO2008132458 A8 WO 2008132458A8
Authority
WO
WIPO (PCT)
Prior art keywords
modulation
treatment
prevention
responses
related methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2008/001460
Other languages
French (fr)
Other versions
WO2008132458A1 (en
Inventor
Grahame James Mckenzie
Bryn Shaun Hardwick
Dirk Rolf Gewert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inion Ltd
Original Assignee
Inion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inion Ltd filed Critical Inion Ltd
Publication of WO2008132458A1 publication Critical patent/WO2008132458A1/en
Publication of WO2008132458A8 publication Critical patent/WO2008132458A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

The present invention relates to compounds of the formula (I) : wherein X is a covalent bond, methylene or ethylene; and R is hydrogen, methyl, ethyl, vinyl, n-propyl, isopropyl, or acetyl for modulating kruppel-like transcription factor 2 (KLF2). Thus the invention relates to the use of these compounds for the modulation of immune responses, and also for the treatment of inflammatory conditions.
PCT/GB2008/001460 2007-04-30 2008-04-25 Compositions useful in the modulation of immune responses and the treatment or prevention of inflammatory responses and related methods Ceased WO2008132458A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SB0708120.1 2007-04-30
SB70812007 2007-04-30

Publications (2)

Publication Number Publication Date
WO2008132458A1 WO2008132458A1 (en) 2008-11-06
WO2008132458A8 true WO2008132458A8 (en) 2009-07-16

Family

ID=39925236

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/001460 Ceased WO2008132458A1 (en) 2007-04-30 2008-04-25 Compositions useful in the modulation of immune responses and the treatment or prevention of inflammatory responses and related methods

Country Status (1)

Country Link
WO (1) WO2008132458A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2451451A (en) * 2007-07-30 2009-02-04 Inion Ltd Osteogenic compounds
US9724329B2 (en) 2010-06-21 2017-08-08 Peter Maccallum Cancer Institute Stimulating immune response
US8987162B2 (en) 2010-08-13 2015-03-24 Ut-Battelle, Llc Hydrothermally stable, low-temperature NOx reduction NH3-SCR catalyst
JP2013032332A (en) * 2011-07-01 2013-02-14 Lintec Corp Immunoactivator
CN118974057A (en) * 2022-02-07 2024-11-15 里帕里安制药股份有限公司 KLF2 inducers and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6926903B2 (en) * 2001-12-04 2005-08-09 Inion Ltd. Resorbable polymer composition, implant and method of making implant
WO2006069000A2 (en) * 2004-12-21 2006-06-29 The Brigham And Women's Hospital, Inc. Klf2 as a mediator of statin activity

Also Published As

Publication number Publication date
WO2008132458A1 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
WO2010008847A3 (en) Pi3k/m tor inhibitors
IL204621A (en) Bicyclic - gamma - amino acid derivatives, compositions comprising the same and uses thereof
MY150596A (en) Hsp90 inhibitors
NZ585460A (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
WO2009102460A3 (en) Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2010063700A3 (en) Novel pyrazole-4 -n-alkoxycarboxamides as microbiocides
WO2009117676A3 (en) Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase
WO2010003475A3 (en) Novel pyrrolidone derivatives for use as metap-2 inhibitors
MX2010002904A (en) N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors.
WO2008030744A3 (en) Inhibitors of c-met and uses thereof
WO2010036998A3 (en) Indole and indoline derivatives and methods of use thereof
MX2010003156A (en) Tetrazole-substituted aryl amide derivatives and uses thereof.
WO2006122188A3 (en) Tripeptides as hepatitis c virus inhibitors
WO2009016460A8 (en) Pyrazole compounds and their use as raf inhibitors
MY150542A (en) Cmet inhibitors
WO2014070639A3 (en) Cosmetic composition comprising hydrophilic organosilanes
WO2006092213A8 (en) Pyrazolylcarboxanilides
WO2009051244A1 (en) Heterocyclic compound
WO2009047298A3 (en) Dimers of harmol or of its derivatives and uses thereof
AU2008303600A8 (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
WO2011008312A3 (en) Indole and indoline derivatives and methods of use thereof
AU2009319796A8 (en) Substituted octahydrocyclopnta (c) pyrrol-4 -amines as calcium channel blockers
AU2008258588A8 (en) Anti -inflammatory substituted cyclobutenedione compounds
WO2010151479A3 (en) Polyhydroxy-diamines as low odor, low voc multi-functional additives for paints and coatings
WO2008132458A8 (en) Compositions useful in the modulation of immune responses and the treatment or prevention of inflammatory responses and related methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08737106

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO R.112(1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 08737106

Country of ref document: EP

Kind code of ref document: A1